EA202190249A1 - Пептидные соединения и их терапевтическое применение - Google Patents
Пептидные соединения и их терапевтическое применениеInfo
- Publication number
- EA202190249A1 EA202190249A1 EA202190249A EA202190249A EA202190249A1 EA 202190249 A1 EA202190249 A1 EA 202190249A1 EA 202190249 A EA202190249 A EA 202190249A EA 202190249 A EA202190249 A EA 202190249A EA 202190249 A1 EA202190249 A1 EA 202190249A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- therapeutic application
- peptide compounds
- dexamethasone
- mice
- reducing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL26055518 | 2018-07-11 | ||
| PCT/IL2019/050774 WO2020012478A2 (en) | 2018-07-11 | 2019-07-10 | Peptide compounds and therapeutic uses of same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202190249A1 true EA202190249A1 (ru) | 2021-05-21 |
Family
ID=69141375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202190249A EA202190249A1 (ru) | 2018-07-11 | 2019-07-10 | Пептидные соединения и их терапевтическое применение |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11912790B2 (enExample) |
| EP (2) | EP4566617A3 (enExample) |
| JP (2) | JP7395517B2 (enExample) |
| KR (1) | KR102880543B1 (enExample) |
| CN (1) | CN112351989B (enExample) |
| AU (2) | AU2019300567B2 (enExample) |
| BR (1) | BR112020024748A2 (enExample) |
| CA (1) | CA3100961A1 (enExample) |
| CO (1) | CO2021001290A2 (enExample) |
| EA (1) | EA202190249A1 (enExample) |
| ES (1) | ES3026158T3 (enExample) |
| HR (1) | HRP20250746T1 (enExample) |
| HU (1) | HUE072141T2 (enExample) |
| IL (2) | IL280101B2 (enExample) |
| MX (1) | MX2021000264A (enExample) |
| PL (1) | PL3820882T3 (enExample) |
| RS (1) | RS66946B1 (enExample) |
| SG (1) | SG11202012773QA (enExample) |
| UA (1) | UA130911C2 (enExample) |
| WO (1) | WO2020012478A2 (enExample) |
| ZA (1) | ZA202100587B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11912790B2 (en) | 2018-07-11 | 2024-02-27 | Immunity Pharma Ltd. | Peptide compounds and therapeutic uses of same |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL272074B2 (en) * | 2020-01-15 | 2024-12-01 | Immunity Pharma Ltd | Peptide compounds and methods of treating diseases using same |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| JPS4843906B1 (enExample) * | 1970-08-11 | 1973-12-21 | ||
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| US6432407B1 (en) * | 1995-12-12 | 2002-08-13 | Takara Shuzo Co., Ltd. | Antigenic protein originating in malassezia |
| WO1997044447A2 (en) * | 1996-05-03 | 1997-11-27 | President And Fellows Of Harvard College | Transcriptional activation system, activators, and uses therefor |
| US6861256B2 (en) * | 1997-05-15 | 2005-03-01 | The General Hospital Corporation | Therapeutic and diagnostic tools for impaired glucose tolerance conditions |
| GB9711148D0 (en) * | 1997-05-31 | 1997-07-23 | Peptide Therapeutics Ltd | Human MAFA |
| EP0928968A1 (en) | 1998-01-12 | 1999-07-14 | Universität Basel | Screening method for apoptosis and necrosis |
| US20090087878A9 (en) * | 1999-05-06 | 2009-04-02 | La Rosa Thomas J | Nucleic acid molecules associated with plants |
| CA2443314C (en) | 2001-04-03 | 2006-03-21 | The Board Of Trustees Of The Leland Stanford Junior University | Method of imaging cell death in vivo |
| US20040204340A1 (en) * | 2003-04-11 | 2004-10-14 | Guilford Pharmaceuticals, Inc. | Polyprolyl inhibitors of cyclophilin |
| AU2005276117C1 (en) | 2004-08-23 | 2013-04-18 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Peptide inhibitors for mediating stress responses |
| EP1843779A2 (en) * | 2005-02-01 | 2007-10-17 | Attenuon, LLC | Compositions containing the anti-angiogenic phscn-peptide |
| US7704953B2 (en) | 2006-02-17 | 2010-04-27 | Mdrna, Inc. | Phage displayed cell binding peptides |
| JP2007228925A (ja) * | 2006-03-02 | 2007-09-13 | Kaneka Corp | 新規酸化酵素及びそれを用いたグリオキサールの製造方法 |
| JP5351495B2 (ja) * | 2008-11-05 | 2013-11-27 | 国立大学法人東北大学 | スーパーオキシドディスムターゼを用いるアセトアルデヒド分解方法 |
| WO2011033511A1 (en) * | 2009-09-17 | 2011-03-24 | Ramot At Tel-Aviv University Ltd. | Peptides for the treatment of oxidative stress related disorders |
| WO2011126882A2 (en) * | 2010-03-30 | 2011-10-13 | American Type Culture Collection | Therapeutic peptides and their derivatives and therapeutic uses thereof |
| EP2593595B1 (en) * | 2010-07-16 | 2020-03-11 | Avantgen, Inc. | Novel peptides and uses thereof |
| WO2012087964A1 (en) * | 2010-12-23 | 2012-06-28 | Codexis, Inc. | Gene disruptants producing fatty acyl-coa derivatives |
| EP3263127B1 (en) | 2011-05-23 | 2019-08-21 | Yeda Research and Development Co. Ltd | Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same |
| US20140271666A1 (en) * | 2013-03-14 | 2014-09-18 | Immune Pharmaceuticals Ltd. | Use of anti-eotaxin antibodies for treating inflammatory bowel disease |
| US20160039877A1 (en) * | 2013-03-15 | 2016-02-11 | Shenzhen Hightide Biopharmaceutical, Ltd. | Compositions and methods of using islet neogenesis peptides and analogs thereof |
| US8802633B1 (en) | 2013-03-18 | 2014-08-12 | Board Of Regents, The University Of Texas System | Autophagy-inducing peptide analogs |
| HUE049261T2 (hu) * | 2014-07-15 | 2020-09-28 | Yissum Research And Development Company Of The Hebrew Univ Of Jerusalem Ltd | CD44 izolált polipeptidek és alkalmazásaik |
| US9453061B2 (en) * | 2014-08-06 | 2016-09-27 | Brown University | Method and compositions for treatment of calcineurin-related diseases |
| CA3172682A1 (en) | 2015-04-23 | 2016-10-27 | Nantomics, Llc | Cancer neoepitopes |
| WO2017011338A1 (en) | 2015-07-10 | 2017-01-19 | President And Fellows Of Harvard College | Sortase-mediated coupling of immunogenic polysaccharide-protein conjugates and their use |
| JP7395517B2 (ja) | 2018-07-11 | 2023-12-11 | イミュニティ ファルマ リミテッド | ペプチド化合物およびその治療的用途 |
| IL272074B2 (en) | 2020-01-15 | 2024-12-01 | Immunity Pharma Ltd | Peptide compounds and methods of treating diseases using same |
-
2019
- 2019-07-10 JP JP2020573032A patent/JP7395517B2/ja active Active
- 2019-07-10 CN CN201980041027.6A patent/CN112351989B/zh active Active
- 2019-07-10 WO PCT/IL2019/050774 patent/WO2020012478A2/en not_active Ceased
- 2019-07-10 CA CA3100961A patent/CA3100961A1/en active Pending
- 2019-07-10 UA UAA202100550A patent/UA130911C2/uk unknown
- 2019-07-10 EP EP25167540.1A patent/EP4566617A3/en active Pending
- 2019-07-10 SG SG11202012773QA patent/SG11202012773QA/en unknown
- 2019-07-10 ES ES19752749T patent/ES3026158T3/es active Active
- 2019-07-10 EP EP19752749.2A patent/EP3820882B1/en active Active
- 2019-07-10 EA EA202190249A patent/EA202190249A1/ru unknown
- 2019-07-10 RS RS20250622A patent/RS66946B1/sr unknown
- 2019-07-10 IL IL280101A patent/IL280101B2/en unknown
- 2019-07-10 HU HUE19752749A patent/HUE072141T2/hu unknown
- 2019-07-10 KR KR1020217004105A patent/KR102880543B1/ko active Active
- 2019-07-10 IL IL317252A patent/IL317252A/en unknown
- 2019-07-10 PL PL19752749.2T patent/PL3820882T3/pl unknown
- 2019-07-10 HR HRP20250746TT patent/HRP20250746T1/hr unknown
- 2019-07-10 US US17/254,867 patent/US11912790B2/en active Active
- 2019-07-10 AU AU2019300567A patent/AU2019300567B2/en active Active
- 2019-07-10 BR BR112020024748-0A patent/BR112020024748A2/pt unknown
- 2019-07-10 MX MX2021000264A patent/MX2021000264A/es unknown
-
2021
- 2021-01-27 ZA ZA2021/00587A patent/ZA202100587B/en unknown
- 2021-02-05 CO CONC2021/0001290A patent/CO2021001290A2/es unknown
-
2023
- 2023-11-29 JP JP2023201767A patent/JP7682248B2/ja active Active
-
2024
- 2024-02-26 US US18/586,715 patent/US20240190919A1/en active Pending
- 2024-12-16 AU AU2024278477A patent/AU2024278477B2/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11912790B2 (en) | 2018-07-11 | 2024-02-27 | Immunity Pharma Ltd. | Peptide compounds and therapeutic uses of same |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20210176A (es) | Anticuerpos estabilizadores de trem2 | |
| CO2021001912A2 (es) | Composiciones anti-cd112r y métodos | |
| EA202092306A1 (ru) | Анти-cd24 композиции и их применения | |
| MX2021013662A (es) | Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos. | |
| EA202092945A1 (ru) | Различные антигенсвязывающие домены, новые платформы и другие улучшения для клеточной терапии | |
| MX2025000260A (es) | Proteina de union al antigeno anti-steap1 | |
| EA202190906A1 (ru) | Рекомбинантное получение препаратов пептидов коллагена и их применение | |
| EA202091130A1 (ru) | Лиофилизованный препарат моноклонального антитела к транстиретину | |
| EA201891589A1 (ru) | Условно активные гетеродимерные полипептиды и способы их применения | |
| MX2019007554A (es) | Proteínas de uníon al antígeno anti-neuropilina, y sus métodos de uso. | |
| NZ737796A (en) | Anti-tau antibodies and methods of use | |
| GT201400057A (es) | 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante | |
| IL280145A (en) | Methods and compositions using recombinant dendritic cells for cancer therapy | |
| HRP20260016T1 (hr) | Modificirani lipidirani peptidi lanca relaksina b i njihova terapijska upotreba | |
| MX2021015160A (es) | Anticuerpos de receptor de peptido natriuretico 1 y metodos de uso. | |
| EA202090184A3 (ru) | Пептидные композиции и способы использования | |
| IL281605A (en) | B*44 restricted peptides for use in immunotherapy against cancers and related methods | |
| MX2020009465A (es) | Anticuerpos anti-klk5 y metodos de uso. | |
| BR112021013206A2 (pt) | Bibliotecas de peptídeos e respectivos métodos de uso | |
| EA202191058A1 (ru) | Антитела против муцина-16 и способы их применения | |
| EA202191081A1 (ru) | Новые раковые антигены и сопутствующие способы | |
| MX2024012582A (es) | Composiciones farmaceuticas de proteinas terapeuticas y metodos de uso | |
| EA202191403A1 (ru) | Композиция с высокой концентрацией белка | |
| MX2018009499A (es) | Anticuerpos monoclonales especificos de egfl6 y metodos de su uso. | |
| CL2019003167A1 (es) | Proteínas de unión al antígeno anti-jagged1. |